HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Macrophage activation syndrome with acute hepatitis E during tocilizumab treatment for rheumatoid arthritis.

Abstract
Tocilizumab is a humanized antibody against the membrane and soluble receptors for interleukin-6. Tocilizumab is among the disease-modifying antirheumatic drugs (DMARDs) used to treat moderate-to-severe active rheumatoid arthritis (RA) refractory to conventional DMARDs. We report a case of macrophage activation syndrome that complicated acute hepatitis E and started within 24hours after the fourth tocilizumab infusion in a patient with RA.
AuthorsMarie Leroy, Guillaume Coiffier, Charlotte Pronier, Louise Triquet, Aleth Perdriger, Pascal Guggenbuhl
JournalJoint bone spine (Joint Bone Spine) Vol. 82 Issue 4 Pg. 278-9 (Jul 2015) ISSN: 1778-7254 [Electronic] France
PMID25791259 (Publication Type: Case Reports, Journal Article)
CopyrightCopyright © 2015 Société française de rhumatologie. Published by Elsevier SAS. All rights reserved.
Chemical References
  • Antibodies, Monoclonal, Humanized
  • tocilizumab
Topics
  • Acute Disease
  • Adult
  • Antibodies, Monoclonal, Humanized (administration & dosage)
  • Arthritis, Rheumatoid (complications, drug therapy)
  • Female
  • Hepatitis E (complications)
  • Humans
  • Infusions, Intravenous
  • Macrophage Activation Syndrome (etiology)
  • Severity of Illness Index

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: